MDX-2001-101研究协议:一期I/IIa,多中心,首次在人体上,开放标签的临床试验,评估MDX2001单疗法在患有晚期固体瘤的患者中
Ecaterina Dumbrava1, Anna Minchom2, Jason Henry3
1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Future oncology (London, England)
|January 6, 2026
概括
MDX2001,一种新的四重特异性抗体,向细胞介质-上皮转变因子 (c-MET) 和热囊细胞抗原2 (TROP2),将T细胞引导到瘤. 这种抗体表现出强烈的抗瘤活性,并将在I/IIa期临床试验中进行评估.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 抗体工程 抗体工程
背景情况:
- MDX2001是一种四重特异性T细胞引入扩展抗体.
- 它的目标是细胞介质-上皮转变因子 (c-MET),热囊细胞抗原2 (TROP2),CD3和CD28.
- 在各种瘤类型的临床前研究中,MDX2001显示出强大的抗瘤活性.
研究的目的:
- 评估MDX2001在患有晚期固体瘤的患者的安全性和耐受性.
- 评估MDX2001.1.的抗瘤作用.
- 为了确定最大耐受剂量 (MTD) 和推的第二阶段剂量 (RP2D).
主要方法:
- 研究MDX-2001-101是一个多中心,开放标签,I/IIa期临床试验.
- 阶段Ia涉及使用贝叶斯最佳间隔设计的剂量升级.
- 阶段Ib和IIa分别涉及剂量扩大和指示扩大.
主要成果:
- 临床前研究表明MDX2001.1.具有强大的抗瘤活性.
- 临床试验旨在评估安全性,耐受性和抗瘤作用.
- 临床试验的具体结果正在等待.
结论:
- MDX2001是一种有前途的T细胞参与扩展抗体,具有已证明的临床前疗效.
- 该I/IIa期试验将为高级固体瘤提供关键的安全性和有效性数据.
- MDX2001有可能为癌症患者提供一种新的治疗选择.
关键词:
CD28 CD28 CD28 CD28 CD28 CD28 CD28 CD28 CD28 CD28 CD28 CD28 CD28 CD28 CD28 CD28 CD28 CD28CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD3 CD4 CD4 CD4 CD4 CD4 CD4 CD5 CD5 CD5 CD5 CD6 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD7 CD7MDX2001 年的MDX2001年这就是TROP2的原因.先进的固体瘤是先进的在c-met上见到了.多种特异性的T细胞引诱剂.研究协议研究协议.
相关概念视频
01:11Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
01:16Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
143
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
143
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
200
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
200